The concept of MolecularMD grew out of discussions with Oregon Health Science University (OHSU) investigators, where the... Read More >   Underlying each type of cancer is a genetic abnormality that leads to deregulated cellular proliferation. In the effort to develop therapies that target these molecular consequences, the appropriate molecular diagnostics can help define the path to regulatory approval and improved patient survival. MolecularMD provides molecular testing services to support the clinical development and regulatory approval of novel targeted cancer therapies. Our core expertise rests in DNA, RNA and other complimentary molecular assays designed to select responsive patient populations and monitor treatment efficacy. MolecularMD was founded based on the translational medicine accomplishments of Drs. Brian Druker and Michael Heinrich of the Oregon Health and Science University. They seek to improve cancer patient survival by linking molecular response to effective molecular cancer therapy.